Clinical features and prognosis of XXXX : 75 cases from China.

@entity1 @entity11533 @entity1910 @entity625 @entity6737 @entity409 @entity221 @entity1851
UNASSIGNED: This study evaluated the clinical characteristics, treatment outcomes, and complications of @entity1 with @entity11533 ( @entity11533 ) in our local Chinese population. @entity1 with @entity11533 attending our hospital from 2008 to 2011 were identified and followed up. Their clinical and laboratory features at presentation, as well as their disease progression, treatments, and outcomes were recorded and compared with other reported series. A total of 75 @entity1 with @entity11533 were identified. Forty-four were female. Thirty-nine had disease onset between 16 and 35 years of age. The most common presenting features were @entity221 (96%), @entity625 (57.33%), @entity1910 (78.67%), and sore throat (49.3%). The acute phase response was marked in most @entity1 , with elevated erythrocyte sedimentation rates (77.05%) and @entity1851 levels (84.06%). @entity6737 was present in 74.14% of cases, and serum ferritin (SF) levels declined after treatment in most cases. @entity409 were usually transient, but were more severe in 5 @entity1 . Most @entity1 (92%) required corticosteroid therapy; of these, 33.3% also received disease-modifying antirheumatic drugs or immunosuppressive drugs. Sixty-four and 45.33% @entity1 with @entity11533 achieved partial and complete remission, respectively, after 2 weeks of treatment, and 92% and 74.67%, respectively, after 1 month. The cumulative relapse rate was 45.3%. @entity1 with @entity11533 had complex symptoms with no specific laboratory findings. Reduced SF levels after treatment and @entity409 may be used to follow treatment outcome.
